Hematopoietic stem cell transplantation for systemic lupus erythematosus

Research output: Contribution to journalArticle

Abstract

Many institutions worldwide are conducting clinical studies using immunoablative therapy followed by hematopoietic stem cell transplantation for the treatment of SLE. Interpretation of these studies will be complicated by the differences in patient selection, conditioning regimens, and the method of stem cell collection. A major concern with this approach is that autoreactive effector cells will be re-infused with the autologous graft. The recent demonstration that immunoablative therapy (cyclophosphamide 200 mg/kg) can be safely delivered without the need for stem cell rescue offers a potential way to circumvent this problem. Early results employing immunoablative therapy, with or without stem cell rescue, are encouraging; however, longer follow-up and additional patients are necessary to validate this approach.

Original languageEnglish (US)
Pages (from-to)377-387
Number of pages11
JournalRheumatic Disease Clinics of North America
Volume26
Issue number2
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Hematopoietic stem cell transplantation for systemic lupus erythematosus'. Together they form a unique fingerprint.

  • Cite this